This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Metacrine Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Dave Maggio

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Equillium acquires Metacrine to extend cash runway through 2024

Sep 06

Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform

Jun 14

Metacrine completes enrollment in mid-stage NASH trial

Jun 02

Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH

Jan 05

What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?

Dec 16

Metacrine reports Q3 results

Nov 12

CEO

Dave Maggio (64 yo)

less than a year

Tenure

Mr. David M. Maggio, also known as Dave, serves as President and Secretary of Otonomy, Inc. since March 31, 2023. He serves as Chief Business Officer, President, Chief Executive Officer, Secretary, Treasur...

This company listing is no longer active

Metacrine Management

Management criteria checks 0/4

Key information

Recent management updates

Metacrine, Inc. Appoints Michael York as Chief Executive Officer

Metacrine, Inc., Annual General Meeting, May 18, 2022

Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

Metacrine, Inc. Announces Board Changes

Metacrine, Inc. Announces Resignation of Catherine Lee as EVP, General Counsel and Corporate Secretary

Recent updates

Metacrine, Inc.(OTCPK:MTCR) dropped from NASDAQ Composite Index

Metacrine, Inc. Appoints Michael York as Chief Executive Officer

Metacrine Receives the Delisting Notice from Nasdaq

Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. (NasdaqCM:MTCR) from a group of shareholders.

Price target decreased to US$0.50

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium acquires Metacrine to extend cash runway through 2024

Price target decreased to US$1.00

Metacrine, Inc., Annual General Meeting, May 18, 2022

Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022

Metacrine, Inc. Announces Resignation of Trisha Millican as Chief Financial Officer

Metacrine, Inc. Announces Board Changes

Metacrine, Inc. Announces Resignation of Catherine Lee as EVP, General Counsel and Corporate Secretary

Price target increased to US$6.17

Metacrine, Inc.(NasdaqGM:MTCR) dropped from Russell Microcap Growth Index

Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform

Metacrine, Inc. Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

Metacrine completes enrollment in mid-stage NASH trial

President recently bought US$75k worth of stock

Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

Metacrine Accelerates MET409 Clinical Development Milestone

Independent Director has left the company

Metacrine, Inc. Provides Interim Data from the Phase 2a Trial of MET642 and Topline Results from a Phase 2a Trial of MET409

Independent Director has left the company

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference

Metacrine, Inc. Initiates Phase 2a Trial of Met642 for the Treatment of Patients with Nash

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

New 90-day high: US$10.82

Metacrine, Inc. Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH

Metacrine, Inc. Reports Positive Results from Phase 1 Trial of MET642

What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?

Metacrine reports Q3 results

Metacrine, Inc. to Present New Data from MET409 Program in Nash at AASLD's the Liver Meeting Digital Experience(TM)

Metacrine, Inc. has completed an IPO in the amount of $85.02 million.

CEO

Tenure